4.8 Article

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Journal

CANCER CELL
Volume 27, Issue 4, Pages 574-588

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2015.03.008

Keywords

-

Funding

  1. Cancer Research UK [A5317, C5759/A12328]
  2. Japan Brain Foundation
  3. Uehara Memorial Foundation
  4. NIHR Royal Marsden Hospital/Institute of Cancer Research Biomedical Research Centre for Cancer
  5. Wellcome Trust [100282/Z/12/Z]
  6. EU Marie-Curie initiative [329047]
  7. Cancer Research UK [17240, 15154, 19279] Funding Source: researchfish
  8. The Francis Crick Institute [10144, 10009, 10147] Funding Source: researchfish
  9. Grants-in-Aid for Scientific Research [15H05949] Funding Source: KAKEN

Ask authors/readers for more resources

Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720. Initially, melanoma cells respond to PLX4720, but rapid reactivation of ERK/MAPK is observed in areas of high stromal density. This is linked to paradoxical activation of melanoma-associated fibroblasts by PLX4720 and the promotion of matrix production and remodeling leading to elevated integrin beta 1/FAK/Src signaling in melanoma cells. Fibronectin-richmatrices with 3-12 kPa elastic modulus are sufficient to provide PLX4720 tolerance. Co-inhibition of BRAF and FAK abolished ERK reactivation and led to more effective control of BRAF-mutant melanoma. We propose that paradoxically activated MAFs provide a safe haven'' for melanoma cells to tolerate BRAF inhibition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available